These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Anticoagulation in hemodialysis sessions with a low molecular weight heparin (CY 222, Choay). Dosage studies in chronic hemodialysis. Its use in patients at high risk of hemorrhage]. Dieval J; Morinière P; Roussel B; Bayrou B; Fournier A; Delobel J J Mal Vasc; 1987; 12 Suppl B():114-8. PubMed ID: 2834482 [TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis. Grau E; Sigüenza F; Maduell F; Linares M; Olaso MA; Martinez R; Caridad A Nephron; 1992; 62(1):13-7. PubMed ID: 1331831 [TBL] [Abstract][Full Text] [Related]
4. Use of single dose low-molecular-weight heparin in long hemodialysis. Lai KN; Ho K; Li M; Szeto CC Int J Artif Organs; 1998 Apr; 21(4):196-200. PubMed ID: 9649059 [TBL] [Abstract][Full Text] [Related]
5. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Anastassiades E; Ireland H; Flynn A; Lane DA; Curtis JR Nephrol Dial Transplant; 1990; 5(2):135-40. PubMed ID: 2162506 [TBL] [Abstract][Full Text] [Related]
6. [Use in hemodialysis and hemofiltration of CY 216 (Fraxiparine) administered via intravenous bolus in patients with acute and chronic renal insufficiency with and without hemorrhagic risk]. Steinbach G; Bosc C; Caraman PL; Azoulay E; Olry L; D'Azemar P; Chopin J Nephrologie; 1990; 11(1):17-21. PubMed ID: 2165223 [TBL] [Abstract][Full Text] [Related]
7. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829 [TBL] [Abstract][Full Text] [Related]
8. Use of low-dose low molecular weight heparin in hemodialysis. Lai KN; Wang AY; Ho K; Szeto CC; Li M; Wong LK; Yu AW Am J Kidney Dis; 1996 Nov; 28(5):721-6. PubMed ID: 9158210 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser. Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946 [TBL] [Abstract][Full Text] [Related]
10. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Lord H; Jean N; Dumont M; Kassis J; Leblanc M Am J Nephrol; 2002; 22(1):58-66. PubMed ID: 11919404 [TBL] [Abstract][Full Text] [Related]
11. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F Nephron; 2002; 92(3):589-600. PubMed ID: 12372942 [TBL] [Abstract][Full Text] [Related]
12. Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin. Reach I; Luong N; Chastang C; Chakroun M; Mirshahi S; Mirshahi MC; Soria J; Desmichels D; Baumelou A Artif Organs; 2001 Jul; 25(7):591-5. PubMed ID: 11493282 [TBL] [Abstract][Full Text] [Related]
13. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation. Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the injection of low-molecular weight heparin in the arterial vs. venous blood line for preventing extracorporeal circuit clotting during hemodialysis. Belmouaz M; Goussard G; Joly F; Grand F; Sibille A; Ecotiere L; Desport E; Bauwens M; Thierry A; Bridoux F Hemodial Int; 2022 Jul; 26(3):314-322. PubMed ID: 35014175 [TBL] [Abstract][Full Text] [Related]
15. A cross-over study of a new low molecular weight heparin (Logiparin) in hemodialysis. Koutsikos D; Fourtounas C; Kapetanaki A; Dalamanga A; Tzanatos H; Agroyannis B; Kopelias I; Bosiolis B; Rammos G; Bovoleti O; Sallum G; Darema M Int J Artif Organs; 1996 Aug; 19(8):467-71. PubMed ID: 8841845 [TBL] [Abstract][Full Text] [Related]
16. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis. Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422 [TBL] [Abstract][Full Text] [Related]
17. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis. Christidou FN; Frangia TK; Bamichas GI; Gionanlis LC; Natse TA; Georgoulis IE; Sombolos KI Int J Clin Pharmacol Ther; 2005 Jul; 43(7):335-8. PubMed ID: 16035376 [TBL] [Abstract][Full Text] [Related]